Skip to content
Company Analysis

Hyperfine, Inc. HYPR

A comprehensive view of key metrics, scores, and financial health for Hyperfine, Inc.

Overview of Hyperfine, Inc.

HYPR NGM
Healthcare Medical Devices Framework: Medical Devices & Diagnostics Micro Cap
Hyperfine, Inc. (HYPR), is a Micro Cap company, in the Medical Devices industry, last closed at $1.36, about 0.0% overvalued vs fair value, +88.4% 1Y return, ranked 824/1122 in sector.
USD 1.36
-4.23%
(Delayed)
• Vol 90d: 67.6%
52-Week Range
Market Cap
$138.98M
Enterprise Value
$104.14M
Overall Score
View breakdown
Overall
Growth
Fair
Profitability
Weak
Health
Weak
Efficiency
Fair
Valuation
Fair
Growth
Fair
Profitability
Weak
Health
Weak
Efficiency
Fair
Valuation
Fair
Completeness: 70%
Confidence: 46%
Updated: Mar 8
Top Beats

Quick Facts

Website https://hyperfine.io
HQ Guilford, CT
Employees 111
Fiscal year Dec 31

Next Events

No upcoming events available.

Fair Value Snapshot

Bear Base Bull
$0
$0
$0
Current: $1.36

Engine Room Money Flow™

Micro Cap

Medical Devices & Diagnostics - Where revenue goes and how value is created

Flow Steps
Total Revenue
$13.6M
5.2%%
Gross Profit
$6.8M
14.6%%
Operating Income (GAAP)
$-37.1M
14.2%%
EBITDA
$-36.0M
14.7%%
Money Flow Bridge
Flow Direction: Money moves from left to right
Components: Breakdown shows composition of each stage
Industry-Specific: Medical Devices & Diagnostics

Quality & Reliability Indicators

Gross Margin
49.8%
Fair

Gross Profit / Revenue — primary moat signal for MedTech. ≥65% indicates IP-protected consumables with strong pricing power.

Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium

Where It Leaks

Cash Flow Health critical
Significant cash flow inefficiencies identified. Multiple high-impact leaks require attention.
1
Active Leaks
0/1
Improving
0
High Impact
1
Critical
Moat Analysis Medical Devices & Diagnostics

Competitive Advantage Assessment

Evaluating Hyperfine, Inc.'s durable competitive advantages across 6 defense dimensions

Overall Moat Strength
35
/100
Developing
Scores based on quantitative metrics and qualitative factors

Upgrade to unlock interactive defense details

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power & Consumable Moat

Weak
23
Premium
Unlock full defense details

See key signals plus strengths and risks for this moat dimension.

Upgrade for full defense analysis Premium-only evidence and insights.
For informational purposes only. Not investment advice.

Trade-Off Ledger™

Where management spends the performance budget - Growth, Profitability, or Safety

Healthcare: MedTech (Devices & Supplies) vs Industry Peers 83% Coverage
Trade-Off Triangle Visualization A ternary plot showing HYPR's balance between Growth (60.0%), Profitability (20.9%), and Safety (19.1%). Growth 60% Safety 19% Profitability 21%

Click axes to expand details. Marker shows current allocation.

3-Year Trend Analysis Locked
Upgrade to unlock the full 3-year trend analysis and deltas.

Growth

65th percentile vs peers
65
Key Signals
Rev Growth YoY 16.8% 71p Revenue CAGR 3Y 1.05 95p EPS Growth YoY 9.3% 39p Asset Growth YoY -37.5% 8p
Strengths
  • Revenue CAGR 3Y in top 20% of peers (1.05, 95th percentile)
  • Growth above peer median with strong metric coverage (75%)
  • Equity/Assets in top 20% of peers (83.3%, 84th percentile)
Risks

No significant risks identified for this axis.

Profitability

22th percentile vs peers
23
Key Signals
Strengths
Risks
Premium
Unlock full Profitability drilldowns

See the signal-level drivers and insights behind this axis. Upgrade to reveal the full Trade-Off Ledger.

Upgrade Now

Safety

20th percentile vs peers
21
Key Signals
Strengths
Safety drilldowns are available to premium members.

Two Futures

Scenario-based fair value ranges for Hyperfine, Inc..

Loading valuation model...
Unable to Compute Fair Value

This company cannot be valued using standard models.

What this means: The Scenario Theatre requires financial data (revenue, cash flow, shares outstanding) to calculate fair value estimates. This data may be unavailable for:

  • Recently listed companies (IPOs, SPACs)
  • Shell companies or holding companies
  • Companies that haven't filed recent financials
  • Foreign companies with limited data coverage
X.X%
X%XX%
X.X%
-XX%XX%
XX.X%
-XX%XX%
Adjust the sliders above to explore different valuation scenarios.
Unlock Premium
Reveal the full Scenario Theatre
See live sliders, narratives, and full Bear/Base/Bull outcomes.
Upgrade Now
Bear
-
- - -
- upside
-
Base
$-0.36
- - -
- upside
Snapshot base estimate
Bull
-
- - -
- upside
-
Fair Value Range Current: $-
$- $- $-
Actions & Info
Send Feedback
Please select a category.
0/1000